Summary:
Have you or a loved one been diagnosed with relapsed or refractory multiple myeloma?
Medical Condition:
Relapsed or refractory multiple myeloma
Study Summary:
Clinical studies for adults 18 years of age or older with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy.
Study Purpose:
The purpose of these clinical studies is to evaluate the safety and effectiveness of study drugs in patients with relapsed or refractory multiple myeloma (RRMM). A study drug is an investigational medication that has not been approved by regulatory health agencies, such as the Food and Drug Administration (FDA) in the United States. The studies are evaluating whether certain study drugs may improve conditions for patients living with RRMM. The study drugs may be administered as oral tablets/capsules, injections under the skin, or infusions.
Depending on the clinical study, a study drug may be compared with a placebo, which will look just like the study drug but will not contain any active ingredients. Certain study drugs may also be taken with currently approved traditional RRMM combination therapies. Participants may be able to continue taking their standard-of-care RRMM medications while enrolled in a clinical study.
Participants who qualify for a clinical study will receive all study-related exams and study-related laboratory tests at no cost. Compensation for time and travel may also be available. If a clinical study includes a placebo, neither the participant nor the study doctor will know which treatment the participant has been assigned to receive, but in case of an emergency, the study doctor can quickly find out.
Eligibility Criteria:
Eligible participants must: